Prediction of bone density around orthopedic implants delivering bisphosphonate by Stadelmann, Vincent A. et al.
ARTICLE IN PRESS
Journal of Biomechanics 42 (2009) 1206–1211Contents lists available at ScienceDirectjournal homepage: www.elsevier.com/locate/jbiomech
Journal of Biomechanics0021-92
doi:10.1
 Corr
E-mwww.JBiomech.comPrediction of bone density around orthopedic implants
delivering bisphosphonateVincent A. Stadelmann a, Alexandre Terrier a, O. Gauthier b, J.-M. Bouler b, Dominique P. Pioletti a,
a Laboratory of Biomechanical Orthopedics, Institute of Bioengineering, Ecole Polytechnique Fe´de´rale de Lausanne, 1015 Lausanne, Switzerland
b Nantes Atlantique Universite´s, INSERM UMR 791, LIOAD, BP 84215, 44042 Nantes, Francea r t i c l e i n f o
Article history:Accepted 13 March 2009
The ﬁxation of an orthopedic implant depends strongly upon its initial stability. Peri-implant bone may
resorb shortly after the surgery. This resorption is directly followed by new bone formation andKeywords:
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implants ﬁxation strengthening, the so-called secondary ﬁxation. If the initial stability is not reached,
the resorption continues and the implant ﬁxation weakens, which leads to implant loosening. Studies
with rats and dogs have shown that a solution to prevent peri-implant resorption is to deliver
bisphosphonate from the implant surface.
The aims of the study were, ﬁrst, to develop a model of bone remodeling around an implant
delivering bisphosphonate, second, to predict the bisphosphonate dose that would induce the maximal
peri-implant bone density, and third to verify in vivo that peri-implant bone density is maximal with the
calculated dose.
The model consists of a bone remodeling equation and a drug diffusion equation. The change in bone
density is driven by a mechanical stimulus and a drug stimulus. The drug stimulus function and the
other numerical parameters were identiﬁed from experimental data. The model predicted that a dose of
0.3mg of zoledronate on the implant would induce a maximal bone density. Implants with 0.3mg of
zoledronate were then implanted in rat femurs for 3, 6 and 9 weeks. We measured that peri-implant
bone density was 4% greater with the calculated dose compared to the dose empirically described
as best.
The approach presented in this paper could be used in the design and analysis processes of
experiments in local delivery of drug such as bisphosphonate.
& 2009 Elsevier Ltd. All rights reserved.1. Introduction
The fate of orthopedic implants seems to be principally
determined at an early stage. Rapid early migrations of stems
have been detected in many asymptomatic hips, often as early as 4
months postoperatively (Karrholm et al., 1994). These early
migrations have been related to an increased risk of clinical
loosening. It has been reported that peri-implant bone resorbs
during a short period after the surgery, probably in response to the
surgically induced trauma, inducing a weakening of the ﬁxation
(Venesmaa et al., 2001). In normal healing conditions, the ﬁxation
strength increases after this initial weakening (Dhert et al., 1998),
but in pathologic conditions, the lack of initial ﬁxation promotes
osteolysis via bone-implant micromotions production, debris
particulate formation and osteoclastic resorption e.g. Stadelmann
et al. (2008).ll rights reserved.
+412169386 60.
ioletti).Based on current knowledge regarding early biological events
at the implant interface, it has been proposed to use bispho-
sphonate to improve the early implant ﬁxation by preventing the
post-surgery osteoclastic resorption (Horowitz and Gonzales,
1996). A recent clinical study showed that post-surgical systemic
administration of clodronate prevents knee prosthesis migration
(Hilding and Aspenberg, 2006). Systemic administration of bi-
sphosphonate presents several adverse effects, like fever, ulcers
and osteonecrosis of the jaw (Dannemann et al., 2007). Since
bones are low-perfused organs, drugs diluted in blood stream
have low probabilities to reach the required locations with
sufﬁcient time or concentration to be effective. To ensure the
availability of bisphosphonate at the peri-implant area, where it is
most needed, methods for local delivery have recently been
addressed (Wermelin et al., 2007; Peter et al., 2006, 2005).
According to these studies, the effect of bisphosphonate released
from implants is non-linearly dose dependent.
In order to calculate the optimal bisphosphonate dosage
to obtain the best implant ﬁxation, a biophysical theory of the
events arising around an implant used for a local delivery of
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remodeling to both the mechanical aspects of peri-implant
situation and the effect of the bisphosphonate. Most of the
existing models of bone remodeling are mechanically driven
e.g. Huiskes et al. (2000). Few attempts exist to address the effect
of systemic bisphosphonate using a model of remodeling
(Hernandez et al., 2001; Pioletti and Rakotomanana, 2004).
However these attempts did not take into account the spatial
diffusion of bisphosphonate when released from a local source.
Therefore, the goals of the present study were triple: ﬁrst, to
develop a model of bone remodeling including mechanical
stimulus as well as the stimulus of bisphosphonate diffusing
from an implant; second, to identify the parameters of the model
from published data; and third to validate the model by verifying
its prediction in vivo.Fig. 1. Simpliﬁed scheme of the experimental system: the titanium implant (Ti) is
coated with a thin layer of hydroxyapatite (HA). Bisphosphonate molecules (stars)
initially loaded in the hydroxyapatite coating are slowly released, diffuse in the
peri-implant trabecular bone (Tb) and inﬂuence the remodeling locally. The
bisphosphonate concentration and the bone density are functions of the distance x
from the coating.2. Materials and methods
2.1. Theoretical developments
The following developments were based on an existing bone model of
remodeling previously developed in our group (Terrier et al., 2005). We extended
the initial model by adding a new internal variable for the drug concentration. The
bone density evolution law was adapted to include this new variable and ﬁnally
we introduced a diffusion law for the drug. In the initial model of remodeling, the
local bone density f varies under the inﬂuence of a mechanical stimulus c. The
choice for this stimulus was the plastic yield stress of Hill (Rakotomanana et al.,
1992). According to this choice, it has been shown that the dependence of the
stimulus in the density f could be written in the following form c ¼ Y/f4 (Terrier
et al., 2005), where Y is a mechanical function that only depends on the stress, but
may, however, depend on space and time through the stress. The bone density
evolution law was characterized by three different regimes: resorption, equili-
brium and densiﬁcation, according to the stimulus level. In the present study, the
extension of the initial model was limited to the densiﬁcation regime. According to
the evolution law (Eq. (1)), bone cells produce extracellular matrix when the
stimulus exceeds a densiﬁcation stimulus threshold cd.
@tf ¼ udðc cdÞ (1)
The rate of densiﬁcation is given by the constant ud, which was determined from
experiment in rats (Terrier et al., 2005).
The extension of the initial model consists in adding the net effect of the drug
as an imbalance of the remodeling process, resulting in a net gain in bone mass.
This effect was introduced through a second stimulus Fdrug, called drug stimulus,
which was deﬁned as a function of a new internal variable, the local drug
concentration k. The model was limited by the following hypothesis: (i) the drug
stimulus depends only on the drug concentration (ii) the mechanical stimulus
does not depend on the drug concentration, and (iii) the bisphosphonate diffuses
following the Fick’s law of diffusion.
The drug stimulus Fdrug(k) is expressed in (% change day1), and the drug
concentration k in (mg/mm3). The rate of densiﬁcation (Eq. (1)) becomes
@tf ¼ udðY=f4 cdÞ þFdrug ðkÞ (2)
completed by drug diffusion
@tk ¼ rðDrkÞ (3)
where D is the effective coefﬁcient of diffusion, which takes into account the
diffusion of the drug into bone marrow, and the tortuosity of cancellous bone.
2.2. Identiﬁcation of the model’s parameters
The unknown parameters of the model are the diffusion coefﬁcient D, the
mechanical function Y(x) and the drug stimulus function Fdrug(k).
First, we experimentally estimated that Dﬃ800 (mm2/day) with an experi-
mental setup using C14-zoledronate diffusing through trabecular bone (Tb)
sections (Peter, 2004).
To identify the other parameters, we used previously published bone density
proﬁles measured around drug-releasing implants (Peter et al., 2005). These
proﬁles were obtained with ﬁve different doses of bisphosphonate, zoledronate in
this case (0, 0.2, 2.1, 8,16mg/implant) corresponding to (0, 0.034, 0.35,1.43, 2.7mg/mm3)
grafted onto the hydroxyapatite (HA) coating of cylindrical titanium implants in
rat condyles at 3 weeks post-op. We simpliﬁed the system of equations (Eqs. (2)
and (3)) with regards to this particular experimental setup, with the following
assumptions: ﬁrst, we reduced the system to a one-dimensional axisymmetric
geometry, where x is the distance from the coating. Second we idealized theboundary conditions by assuming that (i) the hydroxyapatite coating is an inﬁnite
source of bisphosphonate, i.e., k(x ¼ 0, t)k0, and (ii) at 2mm from coating the
drug concentration is null i.e., k(x ¼ 2000,t)0 (Fig. 1).
According to these assumptions we estimated the mechanical parameter Y(x),
by solving the evolution equation (Eq. (2)) for the control group without drug
stimulus. In the following calculations, we further assumed that Y(x) is the same
for all groups, which is reasonable since it only represents the stress state. Finally,
we calculated the drug stimulus Fdrug(k) from the bone density at the coating
surface, where drug concentrations can be assumed to be constant and equal to
that of the coating, for the ﬁve different drug concentrations used in the in vivo
data (Peter et al., 2005). The validity of these assumptions is discussed below.
The bone density was then calculated from the model as a function of the
distance from the coating and is represented in Fig. 2. The calculated density
proﬁles are very similar to the experimental data. The error between experimental
data and calculated data was estimated as the mean relative difference in bone
density for 0oxo150mm and was smaller than 5% for each bisphosphonate
concentration. Computations were processed with custom-made routines of
Mathematica (Wolfram Research, USA).2.3. Validation of the model
The veriﬁcation of the model was done in two steps. First, we evaluated the
bisphosphonate dose which theoretically induces the maximal peri-implant bone
density. We refer to this dose as the ‘‘optimal dose’’ in the following. In the second
step, we veriﬁed that this optimal dose induced in vivo the maximal peri-implant
bone density in a rat model. The in vivo methods used in this part were adapted
from (Peter et al., 2005).2.3.1. Estimation of the optimal concentration
To calculate the optimal drug dose, we solved the theoretical model, with
zoledronate concentration as the variable, to maximize the bone density over a
thickness of 100mm from the coating: Maxk
R 100 mm
0 fðx;kÞdx, and we found that
kopt ¼ 0.044mg/mm3 corresponding to 0.3mg/implant. With this drug dose we
calculated that the average bone surface/total surface (BS/TS) in the 100mm
proximity of the implant would be BS/TS ¼ 61.6, i.e., 2% greater than the highest
density measured so far with 2.1mg/implant.2.3.2. Implants
Twelve titanium alloy cylinders (diameter 3mm; length 5mm) were plasma-
coated with hydroxyapatite and then six implants were soaked in aqueous
solutions of 3106 and six implants in 2.25105mol L1 of zoledronate
(Novartis Pharmaceuticals AG, Switzerland) for 48h. The amount of zoledronate
loaded onto the implants was measured to be, respectively, 0.3 and 2.1mg.2.3.3. Rats
Twelve female 6-month-old Wistar rats were used in this experiment.
The animals had free access to normal diet. The animals were randomly separated
into six different groups representing the two zoledronate doses: 0.3 and
2.1mg/implant and three time points: 3, 6 and 9 weeks (Table 1). Each rat
received one implant in a femoral condyle.
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Fig. 2. (a) Y(x) as a function of x as calculated from the data (points) and the continuous interpolation used for numerical computations (line). (b) The drug stimulus as a
function of drug concentration (points), and the continuous interpolation used for numerical computations (line). (c) Bone density (BS/TS) as a function of the distance from
coating: experimental (points) and model (lines) for the different drug concentrations.
Table 1
Number of animals per group.
Dose (mg/implant) 3w 6w 9w
0.3 2 2 2
2.1 2 2 2
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The local Ethical Committee for Animal studies of the National Veterinary
School of Nantes approved the protocol for the animal experiment. Animals were
kept at the Experimental Surgery Laboratory of the Nantes University according to
the European Community guidelines for the care and use of laboratory animals
(DE86/609/CEE).
Surgical procedures were conducted under general anaesthesia. The implanta-
tions were performed at the distal end of the femurs, at the epiphysometaphyseal
junction. The lateral condyle was exposed and drilled perpendicularly to the long
axis of the femur with two successive bits (2.2 and 2.8mm in diameter) on a low-
speed rotative dental handpiece and under sterile saline irrigation. The implant
was then gently inserted into the cavity under digital pressure. Articular and
cutaneous tissues were closed in two separate layers. After surgery, all the animals
were allowed to move freely in their cages. Animals were killed 3, 6 or 9 weeks
after implantation by intracardiac injection of overdosed sodium pentobarbital
under general anaesthesia.
2.3.5. Preparation for imaging
The femoral ends were then immediately dissected, ﬁxed in glutaraldehyde
solution, and stored in a 4% paraformaldehyde, 0.1% glutaraldehyde in 0.08Mcacodylate buffer. The sample was dehydrated in a series of alcohol solutions. For
the impregnation, the sample was soaked in a mixture of 50% alcohol 1008 and
50% methyl methacrylate (MMA) (Fluka Chemika, Sigma Aldrich Chemie Gmbh,
Steinheim, Germany) during 24h then in pure MMA during 24h. For the inclusion,
the sample was soaked during 2h under vacuum in a solution containing 90%
MMA, 10% dibutylphtalate and 1% benzoyl peroxide (Fluka Chemika), then soaked
in the same solution but enhanced by a polymerization activator (N,N-dimethyl-p-
toluidine) (Fluka Chemika). The polymerization took place at 20 1C during 48h.
Three to four slices of 300-mm-thick perpendicular to the implant were cut from
each sample, using a Microtome saw 1600 (Leica, Nussloch, Germany) diamond
saw.2.3.6. Scanning electron microscopy (SEM)
The slices were carbon-coated. The samples were then observed in a JEOL JSM
6300 scanning electron microscope (JEOL, Tokyo, Japan) using the backscattered
electron detector allowing distinguishing mineralized bone from soft tissue. Then,
these images were used to measure the bone density as a function of the distance
from the coating. The implant surface and trabecular bone regions were deﬁned
manually on each image. To distinguish bone from other tissues: pixels with gray
level between 0 and 62 were considered as calciﬁed bone, while those with gray
level from 63 to 255 were considered as other tissues. We deﬁned successive
regions of interests inside the trabecular bone in the form of series of ten 20-mm-
thick arcs co-centered with the implant. In each arc, the number of bone pixels was
counted and the bone density was deﬁned as bone pixels divided by total pixels in
the arc (BS/TS), using custom algorithms developed with ImageProcessing for
Mathematica.2.3.7. Statistics
The number of slices per animal was accounted for as repetition of density
measurement of the same animal. The mean and the standard error of the mean
for the two animals used in each group are presented.
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3.1. In vivo veriﬁcation of model’s predictions
The model predicted that a drug dose of 0.3mg/implant
maximizes bone density within 100mm layer around the implant.
To verify this prediction, bone density was measured in vivo with
0.3mg/implant and 2.1mg/implant zoledronate at 3, 6 and 9 weeks
in rat condyles. These measures were compared to previous
measures with 0, 0.2 2.1, 8 and 16mg/Zoledronate/implant from
(Peter et al., 2005).
One rat in the 3 weeks—2.1mg zoledronate group and one rat
in the 9 weeks—0.3mg-zoledronate group were excluded from
further analysis, as, for unknown reasons, the implant was not
integrated into bone. A total of thirty-three slices were analyzed
(Table 2).
At three weeks, the model’s predictions were veriﬁed. The
mean bone density of the group with optimal zoledronate dose
was 4% greater than the highest bone density obtained so far in
our previously published results (Fig. 3a). The mean bone density
with 2.1mg zoledronate/implant was in the range of our previous
data. The difference in bone density between the 0.3mg/implant
group and the 2.1mg/implant group observed at 3 weeks, was no
longer observed at 6 and 9 weeks (Fig. 3b).3.2. Evolution of the integration of the implant
The SEM observations conﬁrmed implant integration compar-
able to that previously described (Fig. 4a). The hydroxyapatite
coating evolved at the different time points after implantation. AtTable 2
Number of slices for imaging per group.
Dose (mg/implant) 3w 6w 9w
0.3 6 8 3
2.1 3 6 6
Fig. 3. (a) Mean peri-bone density (BS/TS) in the ﬁrst 100mm layer. The dark bars we
implant Zoledronate. The mean bone density obtained with the optimal calculated 0.3mg
previously published results. (b) Evolution of mean bone density (BS/TS) at 3, 6 and 93 weeks, the bone was in contact with the coating surface, but there
was no sign of resorption in the coating and almost no bone entering
the coating (Fig. 4b). At 6 weeks, the ﬁrst signs of resorption
appeared in the coating. Approximately half of the thickness of the
coating had been resorbed and lacunae could be observed in the
coating (Fig. 4c). At 9 weeks, most of the coating had been resorbed
and newly formed bone was in contact with the titanium surface.
Lacunae were still present inside the coating and some speckles of
bone grew directly from the implant surface (Fig. 4d).
4. Discussion
The principal aims of this projects were ﬁrst, to develop a
theoretical framework of bone remodeling inﬂuenced by local
release of bisphosphonate; second, to identify the parameters of
the model and third, to verify the model’s predictions in vivo.
The development of the model consisted of adding the drug
concentration as a new internal variable to an existing model of
remodeling, completed by a function relating the drug concentra-
tion to the remodeling stimulus. The parameters appearing in this
new model were identiﬁed from our previously published
experimental data (Peter et al., 2005). Next we solved this model
to predict that a dose of 0.3mg of zoledronate grafted on the
implant coating would maximize the peri-implant bone density.
This prediction was ﬁnally conﬁrmed experimentally: with this
calculated dose, the bone density was maximal, compared to
other doses, at 3, 6 and 9 weeks post-op.
The intensity of the effect of bisphosphonate is dose depen-
dent. The theoretical framework developed here shows that the
interpretation of bone density proﬁles has to take into account the
mechanical situation, the drug diffusion and the effect of drug on
the remodeling balance, modeled here by the drug stimulus Fdrug.
The drug stimulus function is the key point of the model. It can
be interpreted as the signature of the drug in a particular animal
model. The shape of this function reﬂects that the drug induces
the imbalance of the remodeling process after the decrease of
osteoclast activity. The shape of the function is concordant with
what is observed in vitro: bisphosphonates, like most drugs, have
a range of concentration with beneﬁcial effects but can produce
adverse effects at higher doses (Fleisch, 2002).re adapted from (Peter et al.) and the light bar represents the group with 0.3mg/
/implant zoledronate was 4% greater than the highest bone density obtained in our
weeks post-op.
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Fig. 4. SEM pictures of implanted condyles: panel (a) shows the bone structure of a condyle implanted with HA-coated implant containing 2.1mg zoledronate at 3 weeks.
The implant integration is qualitatively similar to previously published results. Panel (b) shows a detail of the bone-coating interface at 3 weeks. Bone is not yet entering the
coating. Panel (c) shows the interface at 6 weeks with the ﬁrst signs of coating resorption, and panel (d) shows the interface at 9 weeks with more than 50% of the coating
resorbed.
V.A. Stadelmann et al. / Journal of Biomechanics 42 (2009) 1206–12111210The model presented here is based on several hypotheses
which were consistent with the experimental situation addressed.
We assumed that the model of a cylindrical implant could be
reduced to a one-dimensional geometry. This assumption is
relevant in our situation as we analyzed only the average density
of a very thin layer of bone and we were not interested in
histomorphometry aspects. Moreover, the analyzed slices were
not taken from the extremities of the implants, which are in the
cortical regions of the condyles.
Fick’s law of diffusion for bisphosphonates is certainly a
limitation of the model. However, there is a lack of information
for the diffusion aspect of bisphophonates in human bone and the
use of the experimentally determined effective coefﬁcient of
diffusion (Peter, 2004) can be considered as a ﬁrst approach as an
average diffusion behavior is obtained.
We identiﬁed from experimental data that the loading function
Y(x) increased signiﬁcantly near the implant surface. This
certainly reﬂects the mechanical stress following press-ﬁt inser-
tion and spring-back effect of bone (Kold et al., 2003). With a
different surgical protocol, the stress distribution would certainly
be different, and Y(x) would have to be re-calculated.
In the resolution of our model, we simpliﬁed the boundary
conditions: we set the coating as an inﬁnite source of drug at
constant concentration. The relevance of this assumption for
short-term studies was conﬁrmed by the SEM observations: at
three weeks, the coating was indeed not signiﬁcantly resorbed. It
was probably still protected from osteoclastic resorption by its
content in bisphosphonate. This is concordant with the very low
release rate of zoledronate by hydroxyapatite (Roussiere et al.,
2005). However, this simplifying assumption cannot be used for
long-term studies: we observed that the hydroxyapatite coating
was partially degraded at 6 weeks, and this degradation continued
at 9 weeks. The bisphosphonate concentration in the coating then
certainly decreases signiﬁcantly after 3 weeks. With the second
boundary condition, we assumed that the drug concentration isnegligible at 2mm from the implant surface, which corresponds
to the growth plate and the bone marrow. Since these tissues are
well perfused, the drug is certainly diluted into the blood volume.
The observed degradation of the coating at 6 and 9 weeks, and
the lacunae in resorbed areas might reﬂect the presence of
osteocytes in the newly formed bone–implant interface. This is a
sign of good implant osteointegration at mid- and long-term post-
op with the optimal zoledronate concentration. However, more
histology would be needed to conﬁrm this observation.
Our results are certainly dependent on the choice of the drug
and on the animal model. In the present study, we determined
the drug stimulus function for zoledronate in rats. To extend the
model predictions to other active molecules or other animals, the
ﬁrst step would be to determine the drug stimulus function,
which we called the drug signature, with the speciﬁc drug using
the speciﬁc animal. To our knowledge, none of the required data
for such identiﬁcation with other animals or with different drugs
has been published.
Only a limited number of animals were used in the experi-
mental part of this project. The main objective of this project was
to compare the theoretical model’s outcomes to an in vivo
situation. The experiments were therefore designed to validate
the model rather than to provide new statistically signiﬁcant
experimental results, which would have required a much larger
number of animals.
The principal objective of coating implants with bispho-
sphonate for local delivery is to increase the ﬁxation of the
implant. The pullout force is somehow related to peri-implant
bone density (Peter et al., 2005), but other factors, such as bone
quality, also have an inﬂuence. A mathematical relationship
between histomorphometry of bone and its mechanical capacity
to resist pullout has yet to be determined (Jakobsen et al., 2006).
Thus, the mathematical model presented here only predicts bone
density. More work will be needed to link bone density to implant
ﬁxation strength.
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implants is to obtain sufﬁcient early ﬁxation to ensure long-term
stability, for patients of variable age, daily activity level or bone
quality. Although several studies have shown that implants
delivering bisphophonate improve this ﬁxation, the bisphospho-
nate molecule, the dose, or the animal model have always been
chosen empirically. So the conclusion of this article is to
demonstrate that the theoretical framework presented could be
of great interest to predict the bone formation around implant
delivering bisphosphonate.Conﬂict of interest statement
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